GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $3.97 billion. The enterprise value is $3.93 billion.
Important Dates
The last earnings date was Tuesday, October 28, 2025, before market open.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 28.89 million shares outstanding. The number of shares has increased by 7.19% in one year.
| Current Share Class | 28.89M |
| Shares Outstanding | 28.89M |
| Shares Change (YoY) | +7.19% |
| Shares Change (QoQ) | -3.21% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 93.18% |
| Float | 20.47M |
Valuation Ratios
The trailing PE ratio is 1,906.61 and the forward PE ratio is 58.95. GeneDx Holdings's PEG ratio is 1.73.
| PE Ratio | 1,906.61 |
| Forward PE | 58.95 |
| PS Ratio | 9.68 |
| Forward PS | 8.81 |
| PB Ratio | 13.55 |
| P/TBV Ratio | 37.16 |
| P/FCF Ratio | 256.79 |
| P/OCF Ratio | 119.67 |
| PEG Ratio | 1.73 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 113.19, with an EV/FCF ratio of 254.08.
| EV / Earnings | 1,886.48 |
| EV / Sales | 9.77 |
| EV / EBITDA | 113.19 |
| EV / EBIT | 335.40 |
| EV / FCF | 254.08 |
Financial Position
The company has a current ratio of 2.71, with a Debt / Equity ratio of 0.39.
| Current Ratio | 2.71 |
| Quick Ratio | 2.47 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 2.71 |
| Debt / FCF | 7.32 |
| Interest Coverage | 4.31 |
Financial Efficiency
Return on equity (ROE) is 0.84% and return on invested capital (ROIC) is 2.02%.
| Return on Equity (ROE) | 0.84% |
| Return on Assets (ROA) | 1.62% |
| Return on Invested Capital (ROIC) | 2.02% |
| Return on Capital Employed (ROCE) | 2.88% |
| Revenue Per Employee | $402,190 |
| Profits Per Employee | $2,083 |
| Employee Count | 1,000 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 11.44 |
Taxes
In the past 12 months, GeneDx Holdings has paid $424,000 in taxes.
| Income Tax | 424,000 |
| Effective Tax Rate | 16.91% |
Stock Price Statistics
The stock price has increased by +133.71% in the last 52 weeks. The beta is 2.04, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +133.71% |
| 50-Day Moving Average | 123.48 |
| 200-Day Moving Average | 94.83 |
| Relative Strength Index (RSI) | 66.02 |
| Average Volume (20 Days) | 550,990 |
Short Selling Information
The latest short interest is 3.00 million, so 10.39% of the outstanding shares have been sold short.
| Short Interest | 3.00M |
| Short Previous Month | 2.82M |
| Short % of Shares Out | 10.39% |
| Short % of Float | 14.66% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $402.19 million and earned $2.08 million in profits. Earnings per share was $0.07.
| Revenue | 402.19M |
| Gross Profit | 280.16M |
| Operating Income | 11.72M |
| Pretax Income | 2.51M |
| Net Income | 2.08M |
| EBITDA | 34.72M |
| EBIT | 11.72M |
| Earnings Per Share (EPS) | $0.07 |
Full Income StatementBalance Sheet
The company has $155.08 million in cash and $113.16 million in debt, giving a net cash position of $41.92 million or $1.45 per share.
| Cash & Cash Equivalents | 155.08M |
| Total Debt | 113.16M |
| Net Cash | 41.92M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 292.26M |
| Book Value Per Share | 10.15 |
| Working Capital | 149.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $33.19 million and capital expenditures -$17.72 million, giving a free cash flow of $15.47 million.
| Operating Cash Flow | 33.19M |
| Capital Expenditures | -17.72M |
| Free Cash Flow | 15.47M |
| FCF Per Share | $0.54 |
Full Cash Flow StatementMargins
Gross margin is 69.66%, with operating and profit margins of 2.91% and 0.52%.
| Gross Margin | 69.66% |
| Operating Margin | 2.91% |
| Pretax Margin | 0.62% |
| Profit Margin | 0.52% |
| EBITDA Margin | 8.63% |
| EBIT Margin | 2.91% |
| FCF Margin | 3.85% |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.19% |
| Shareholder Yield | -7.19% |
| Earnings Yield | 0.05% |
| FCF Yield | 0.39% |
Analyst Forecast
The average price target for GeneDx Holdings is $112.22, which is -18.37% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $112.22 |
| Price Target Difference | -18.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 20.32% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 8 |
